Nat Metab:移植器官的低温保存

2019-10-02 Nature自然科研 Nature自然科研

根据《自然-代谢》最新发表的一项研究Succinate accumulation drives schaemiareperfusion injury during organ transplantation,快速冷却动物和人类供体心脏或能减少一种会损害移植后组织的化学物质。这些发现或许可以改进全球有限的捐献器官的保存。

根据《自然-代谢》最新发表的一项研究Succinate accumulation drives schaemiareperfusion injury during organ transplantation,快速冷却动物和人类供体心脏或能减少一种会损害移植后组织的化学物质。这些发现或许可以改进全球有限的捐献器官的保存。



暖温和低温下心脏ATP/ADP比率。来源:Martin et al.

在器官移植领域,一般使用心脏保存液保存供体心脏,但是供体心脏摘取时所发生的化学变化和器官低温保存的具体益处并不十分明了。

英国剑桥大学MRC线粒体生物学研究单位的Mike Murphy、剑桥大学的Kourosh Saeb-Parsy及同事对暖温或低温温度下保存的小鼠、猪和人类心脏进行了详细的代谢分析,发现暖温保存会增加代谢物琥珀酸盐的累积,而这会在心脏重新与血管相连后损害心脏组织。通过注射药物或者低温保存器官,可以防止琥珀酸盐累积,并改善了小鼠心脏移植结局。

作者总结表示,这项研究或能推动研发新药来抑制移植器官中琥珀酸盐的累积,改善移植效果。

原始出处:
Jack L. Martin, Ana S. H. Costa, et al. Succinate accumulation drives ischaemia-reperfusion injury during organ transplantation. Nature Metabolism.  30 September 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896556, encodeId=d95418965561a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 24 20:05:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883899, encodeId=177d1883899f0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 17 05:05:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888071, encodeId=f32518880e14f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Apr 13 17:05:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373878, encodeId=ef203e387808, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Oct 14 00:05:43 CST 2019, time=2019-10-14, status=1, ipAttribution=)]
    2020-06-24 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896556, encodeId=d95418965561a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 24 20:05:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883899, encodeId=177d1883899f0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 17 05:05:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888071, encodeId=f32518880e14f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Apr 13 17:05:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373878, encodeId=ef203e387808, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Oct 14 00:05:43 CST 2019, time=2019-10-14, status=1, ipAttribution=)]
    2020-03-17 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896556, encodeId=d95418965561a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 24 20:05:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883899, encodeId=177d1883899f0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 17 05:05:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888071, encodeId=f32518880e14f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Apr 13 17:05:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373878, encodeId=ef203e387808, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Oct 14 00:05:43 CST 2019, time=2019-10-14, status=1, ipAttribution=)]
    2020-04-13 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896556, encodeId=d95418965561a, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 24 20:05:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883899, encodeId=177d1883899f0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 17 05:05:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888071, encodeId=f32518880e14f, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon Apr 13 17:05:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373878, encodeId=ef203e387808, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Mon Oct 14 00:05:43 CST 2019, time=2019-10-14, status=1, ipAttribution=)]
    2019-10-14 thm112988

    0

相关资讯

Lancet oncol:癌症幸存患儿的实体器官移植率

癌症患儿幸存者常发生严重的慢性疾病。研究人员对癌症患儿因终末器官损伤进行实体器官移植的概率和危险因素进行研究,同时评估这类患儿器官移植后的5年存活率。研究对象为1970年1月1日-1986年12月31日期间,21岁前确诊癌症后存活5年以上的个体。受试者所患的癌症有白血病、淋巴瘤、恶性中枢神经系统肿瘤、神经母细胞瘤、威尔姆斯瘤、骨及软组织肉瘤。共13318位符合要求的患儿,100位进行了实体器官移植

器官移植术后HBV感染诊疗规范(2019版)

HBV是嗜肝双链环状DNA病毒,完整的HBV病毒颗粒为直径约42 nm的球形,由包膜和核心颗粒组成。包膜含HBsAg、糖蛋白和膜脂质,核心颗粒内含双链环状HBV DNA、HBV DNA聚合酶和HBcAg。完整形态的HBV对肝细胞具有强力的感染性,又称Dane颗粒。 1 流行病学 人体对HBV普遍易感,非移植患者HBV主要的传播途径包括血液传播(输血和血制品)、母婴传播(

Circulation:抑制Notch-1可增强器官移植的耐受性!

移植是多种终末期器官疾病患者的最终选择。虽然在免疫抑制方面取得了进展,但由于药物毒性和免疫介导性损伤的阻碍,移植患者的长期预后仍不理想。因此,开发可同时提高移植物存活率和最小化常规免疫抑制的新疗法至关重要。Notch信号通路是一条高度保守的对T细胞分化和功能至关重要的通路,是调控T细胞介导的免疫的研究热点。研究人员对Notch-1在实体器官移植的小鼠和人受体的效应T细胞和调节T细胞(Tregs)中

“人类猴子嵌合体”研究在中国进行,已被迫中止

近日,据相关外媒报道,一个国际研究小组构建出含有人类和猴子细胞的胚胎,为了避免法律问题,这个有争议的项目是在中国进行的。

器官移植术后结核病临床诊疗技术规范(2019版)

结核病是实体器官移植后一种较为少见但后果严重的感染性疾病。随着器官移植受者以及结核病患病人数的增加,需要建立规范的诊疗程序和治疗指导原则,以便合理制定化学治疗和免疫抑制方案。为了进一步规范实体器官移植术后结核病的临床诊疗,中华医学会器官移植学分会组织器官移植学专家和结核病学专家,从实体器官移植术后结核病的流行病学特点、诊断、预防和治疗等方面,在《中国器官移植术后结核病临床诊疗指南(2016 版)》

器官移植术后耐药菌感染诊疗技术规范(2019版)

为了进一步规范实体器官移植术后耐药菌感染的诊断和治疗,中华医学会器官移植学分会组织器官移植学专家和感染学专家,从实体器官移植术后耐药菌感染的情况、国内细菌感染及耐药情况、多重耐药菌感染的抗生素治疗等方面,制订实体器官移植术后耐药菌感染的诊疗技术规范。